Susceptibility testing of amorolfine, bifonazole and ciclopiroxolamine against Trichophyton rubrum in an in vitro model of dermatophyte nail infection

References

• Effendy I, Lecha M, Feuilhade de Chauvin M, Di Chiacchio N, Baran R. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol 2005; 19Suppl. 1:8–12.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Ryder JE, Skinner AR. Treatment of onychomycosis: pros and cons of antifungal agents. J Cutan Med Surg 2004; 8: 25–30.
   PubMed Web of Science ®Google Scholar
• Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Baran R (2005) Treatment options – development of consensus guidelines. J Eur Acad Dermatol Venereol 2005 2005; 19 Suppl. 1:25–33.
   PubMedGoogle Scholar
• Flagothier C, Pierard-Franchimont C, Pierard GE. New insights into the effect of amorolfine nail lacquer. Mycoses 2005; 48: 91–94.
   PubMed Web of Science ®Google Scholar
• Monti D, Saccomani L, Chetoni P, . In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer. Drug Dev Ind Pharm 2005; 31: 11–17.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Baran R. Ciclopirox nail lacquer solution 8% in the 21st century. J Am Acad Dermatol 2000; 43: 96–102.
   PubMed Web of Science ®Google Scholar
• Bonifaz A, Guzman A, Garcia C, Sosa J, Saul A. Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis. Int J Dermatol 1995; 34: 500–503.
   PubMed Web of Science ®Google Scholar
• Osborne CS, Leitner I, Favre B, Ryder NS. Antifungal drug response in an in vitro model of dermatophyte nail infection. Med Mycol 2004; 42: 159–163.
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics (Fachinformation) Batrafen® Nail lacquer (Nagel Batrafen®); Chapter 5 Pharmacodynamic properties; Status Aug 2007.
   Google Scholar
• Li RY, Wan Z, Wang AP, . In vitro susceptibility testing of amorolfine in pathogenic fungi isolated from dermatomycosis patients in China. Mycoses 2004; 47: 402–406.
   PubMedGoogle Scholar
• Jessup CJ, Warner J, Isham N, Hasan I, Ghannoum MA. Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol 2000; 38: 341–344.
   PubMed Web of Science ®Google Scholar
• Plempel M, Regel E, Buchel KH. Antimycotic efficacy of bifonazole in vitro and in vivo. Arzneimittelforschung 1983; 33: 517–524.
   PubMed Web of Science ®Google Scholar
• Feuilhade De Chauvin M, Marie M-D, Claire L. In vitro antifungal activity of amorolfine, bifonazole, ciclopirox and terbinafine against Trichophyton rubrum and Trichophyton mentagrophytes var. interdigitale. . J Eur Acad Dermatol Venereol2003 Suppl. 3; 17:S319.
   Google Scholar
• Favre B, Hofbauer B, Hildering KS, Ryder NS. Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay. J Clin Microbiol 2003; 41: 4817–4819.
   PubMed Web of Science ®Google Scholar
• Santos DH, Hamdan JS. In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes. Med Mycol 2006; 44: 357–362.
   PubMed Web of Science ®Google Scholar
• Hui X, Wester RC, Barbadillo S, . Ciclopirox delivery into the human nail plate. J Pharm Sci 2004; 93: 2545–2548.
   PubMed Web of Science ®Google Scholar
• Polak A. Kinetics of amorolfine in human nails. Mycoses 1993; 36: 101–103.
   PubMed Web of Science ®Google Scholar
• Mensing H, Polak-Wyss A, Splanemann V. Determination of the subungual antifungal activity of amorolfine after 1 month's treatment in patients with onychomycosis: comparison of two nail lacquer formulations. Clin Exp Dermatol 1992; 17Suppl. 1:29–32.
   PubMedGoogle Scholar
• Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000; 43Suppl. 4:57–69.
   Google Scholar
• Tatsumi Y, Yokoo M, Senda H, Kakehi K. Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine. Antimicrob Agents Chemother 2002; 46: 3797–37801.
   PubMed Web of Science ®Google Scholar
• Nakashima T, Nozawa A, Ito T, Majima T. Experimental tinea unguium model to assess topical antifungal agents using the infected human nail with dermatophyte in vitro. J Infect Chemother 2002; 8: 331–335.
   Google Scholar
• Halmy K. Experience with nail lacquers containing amorolfine 5% and ciclopirox 8% in patients with onychomycosis. J Eur Acad Dermatol Venereol 2004; 18Suppl. 1:242.
   Google Scholar
• Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005; 19: 21–29.
   PubMed Web of Science ®Google Scholar